ArticleBMJ global health2025
'Prevalence, experience and awareness of substandard and falsified medicines among the public and healthcare professionals in Jordan'.
Article in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 'Prevalence, experience and awareness of substandard and falsified medicines among the public and healthcare professionals in Jordan'.BMJ global health · 2025Article
- Drivers and strategies to combat substandard and falsified medicines in low- and middle-income countries: A systematic review of qualitative evidence.The journal of medicine accessReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to assess the awareness, experiences and perspectives on substandard and falsified (SF) medicines among the general public and healthcare professionals in Jordan. SF medicines pose a global public health concern, yet data on their prevalence and associated risks in Jordan remain limited.
methodsA cross-sectional study was conducted between January and June 2023 using a convergent mixed-methods approach. Quantitative data were collected through structured surveys administered to 209 members of the public and 136 healthcare professionals (pharmacists and clinicians) recruited via convenience sampling across Jordan's 12 governorates. Surveys were conducted in English and Arabic. Qualitative data from open-ended responses were analysed thematically.
resultsSF medicine awareness was low, with only 24% of the public and 35% of healthcare professionals reporting familiarity with the issue. Of those aware, only 8% (n=17) of the public and 25% (n=34) of healthcare professionals correctly identified SF medicines. Experiences with SF medicines were reported by 17% (n=36) of the public and 26% (n=35) of healthcare professionals, with some respondents describing adverse effects, including severe complications requiring medical intervention. Despite this, 81% of the public and all healthcare professionals who had encountered SF medicines did not report them, citing a lack of awareness of reporting mechanisms. Economic factors and misconceptions about generics were identified as contributing factors to the circulation and use of SF medicines.
conclusionAwareness of SF medicines in Jordan is critically low among both the public and healthcare professionals. The absence of formal reporting systems and economic constraints exacerbates the issue, increasing the risk of exposure to SF medicines. Urgent interventions, including nationwide education campaigns, the establishment of structured reporting mechanisms and policies addressing financial barriers, are essential to mitigating the impact of SF medicines on public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.